| Applied Molecular Transport is a clinical-stage biopharmaceutical company utilizing its proprietary technology platform to design and develop a pipeline of oral and respiratory biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases. Co. has two oral biologics in clinical development. Co.'s product candidate, AMT-101, is in Phase 2 development for patients with ulcerative colitis and related inflammatory indications. Co.'s second product candidate, AMT-126 is in Phase 1 development for diseases related to intestinal epithelium barrier function defects. We show 10 historical shares outstanding datapoints in our coverage of AMTI's shares outstanding history.|
Understanding the changing numbers of AMTI shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like AMTI versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching AMTI by allowing them to research AMTI shares outstanding history
as well as any other stock in our coverage universe.